A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Phase 3 Completed 141 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia.

Timeline

Start: 2001-08
Primary completion: —
Completion: 2002-10

Publications

Results Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004 Aug;65(8):1084-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Risperidone	Other / unclassified	25 mg	Intramuscular
Subject	Risperidone	Other / unclassified	37.5 mg	Intramuscular
Subject	Risperidone	Other / unclassified	50 mg	Intramuscular

A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Summary

Timeline

Publications

Drugs

Indications